⌘K
t
AstraZeneca PLC announced on 02 March 2026, in accordance with UK FCA Disclosure and Transparency Rule 5.6.1, its total voting rights and capital. As at 28 February 2026, AstraZeneca PLC's issued share capital with voting rights was 1,550,966,708 ordinary shares of US$0.25. No shares were held in Treasury, resulting in a total of 1,550,966,708 voting rights.
| Date | 2 Mar 2026 |
| Time | 15:00:00 |
| Category | Capital structure |
| ID | 7830U |
2 March 2026
Transparency Directive
Voting rights and capital
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 28 February 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,550,966,708 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,550,966,708.
The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC